ARK5 represents an interesting clinical target in MM, as dual inhibition of ARK5 and CDK4 in MM by the inhibitor ON123300 led to swift induction of cell cycle arrest, followed by apoptosis. Here, CDK4 is linked to Miyoshi myopathy.